Abstract

Objective

A breath-holding spell (BHS) is defined as an apnea attack following an initial stressful event like anger, sadness, and fear, a painful event like falling or head trauma or any stressful psychology event. This study was designed to assess the comparative efficacy of levetiracetam plus iron and iron alone in reducing the BHS frequency in children aged 6 months to 5 years.

Materials & Method

This study was designed as a double-blinded randomized clinical trial. Sixty patients aged 6 months to 5 years were assigned into two groups, with the first group (A) receiving only iron and the second group (B) receiving levetiracetam plus iron. At the end of the study, the efficacy of therapy was analyzed comparatively in these groups.

Results

In this study, the mean number of attacks was 3.94 ± 2.69 before treatment and 1.71 ± 1.99 after treatment in the group A, while it was 6.39 ± 5.7 before treatment and 0.37 ± 1.03 after treatment in the group B. The mean number of attacks after treatment was lower in group B than in group A. In fact, there was a significant difference between the two groups in terms of the number of attacks after treatment (P = 0.003).

Conclusion

Levetiracetam plus iron is more effective than iron alone in reducing BHSs in children aged 6 months to 5 years.

Keywords: Breath-holding spells, levetiracetam, Iron supplements
Introduction
A breath-holding spell (BHS) is defined as an attack following an initial stressful event such as anger, grief, and fear, a painful stimulus such as falling and head trauma, or any other psychological distress (1, 2). During these attacks, the child starts crying in less than 11 seconds of initial stress, and after a deep inhalation, stops breathing in the exhalation stage, causing facial changes of either cyanosis or pallor. Attacks are sudden and involuntary with benign and self-limited nature, but careful consideration should be given to rule out any serious problem (3, 4).

The age of the onset of BHS is 11.6 months. However, it may occur before 6 months, and in about 11% of cases, the first attack occurs after 2 years of age. Attacks decrease after 2 years of age, and until the age of 4, 11% of children will be attack free; almost all patients will recover by the age of 7. In the majority of articles, the gender of children studied showed a male to female ratio of more than one (5).

The pathophysiology of attacks is a complicated process and is not yet fully discovered. Various studies have been conducted to examine the exact cause and the nature of attacks, and each of them presented a separate mechanism. Some studies on the pathophysiologic mechanism suggested that the underlying cause of breath-holding attacks was the irregularity of the autonomic nervous system (6, 7). In one study on the autonomic nervous system activity, ECG changes such as heart rate, frequency, and length of QT interval during an attack were recorded. The presence of disorders of the respiratory sinus rhythm and long systole was noticed during the attack, indicating the presence of a disorder in the regulation of the autonomic nervous system (8).

Iron deficiency is the most common cause of anemia in the first 2 years of life, a period which can be observed as the BHS peak in children. Some studies have shown that anemia or low levels of red blood cells may be an etiologic factor, and iron supplements may improve BHS in children (9-11). Levetiracetam is a new antiepileptic drug that is structurally similar to piracetam, which has been used in the treatment of BHSs. Previous studies have suggested that piracetam is an anxiety stabilizing agent, and thus, improves BHSs (12, 13). Levetiracetam has fast and complete digestive absorption, but its protein binding is small. The drug and its metabolites are excreted through the urine and have a half-life of about 6-8 hours. The drug does not interact with other antiepileptic drugs, and also, does not affect the pharmacokinetics of other drugs such as contraceptive drugs, digoxin, and warfarin. It is used as an adjunct to control general and partial epilepsy. The exact mechanism of levetiracetam is still unknown, but its side effects are extremely small and do not require any controlled testing (14, 15). According to limited reports regarding the use of new pharmacological methods and the traditional method of using an iron to control BHSs, we designed and implemented this study to evaluate the efficacy of levetiracetam in combination with iron supplementation compared with iron therapy alone in controlling BHSs.

Materials & Method
In this randomized clinical trial, 60 6-month to 5-year-old patients with BHS admitted to the Motahari Hospital of Urmia were enrolled from 16 Oct 2018 to 18 Feb 2019. The exclusion criteria were neurodevelopmental delay, any disorder of the nervous system, and discontinuation of medication during the study.
The patients were randomly assigned into two groups: the first group (A) received only iron supplement at a dose of 5 mg/kg/day (from ferrous sulfate in two divided doses) for three months and the second group (B) started levetiracetam at a dose of 10 mg/kg/day titrating to 40 mg/kg/day (at two doses of Cobel Darou company) and iron at a dose of 5 mg/kg/day (from ferrous sulfate in two divided doses) for three months. All information needed for the research about age, sex, and number of attacks before and after treatment was gathered monthly through follow-up visits and over telephone and entered in checklists for final analysis. The data were analyzed using SPSS version 22 and reported using descriptive statistics (frequency and percentage) and mean ± standard deviation (mean ± SD). A Student’s t-test was used to analyze quantitative data and the Chi-square test to analyze the qualitative variables (and Fisher’s exact test if required). The data were also evaluated using the Kymograph-Smirnov test. The ANOVA test was used in case the data distribution was normal, and the Mann–Whitney U test was used to analyze non-parametric data. P-value <0.05 was considered statistically significant.

Ethical considerations

Agreement of the University’s Ethics Committee was obtained. Ethical considerations Agreement of Urmia university of medical sciences Ethics Committee was obtained (code: IR.UMSU.REC.1397.321). The patients’ dignity was prioritized. All data of the patients were confidential. Conscious informed consent was obtained from the infants’ parents.

Results

This study was conducted on 60 patients with BHS admitted to the Shahid Motahari Hospital in Urmia from 16 Oct 2018 to 18 Feb 2019. The patients were divided into two treatment groups: group A with 28 people receiving ferrous sulfate and the group B with 32 patients receiving ferrous sulfate and Levetiracetame (levebel). The mean ages were 19.6 ± 10.32 months and 17.06 ± 8.46 months in the groups A and B, respectively, with the overall mean age being 18.25 ± 9.38 months. The mean hemoglobin was 10.86 ± 0.99 in the group A and 10.85 ± 0.87 in the group B, and 10.86 ± 0.92 in total. The mean ferritin was 24.65 ± 7.63, 25.02 ± 5.56, and 24.85 ± 6.55 for the group A, the group B, and as the total value, respectively (Tables 1 and 2). There was no significant difference between the two groups regarding age, HB, and ferritin based on the Mann-Whitney U non-parametric test results (Table 2).

Group A consisted of 17 boys and 11 girls compared to group B with 11 boys and 21 girls, making an overall of 28 boys and 32 girls (Table 3-3). There was a significant correlation between the two groups in terms of gender according to the Chi-square test results (P = 0.46); although, its severity was low based on the Cramer’s V test results, with the therapeutic effect being higher in the girls. The mean number of attacks before and after treatment was 4.39 ± 2.69 and 1.71 ± 1.99 in the group A and 6.39 ± 5.07 and 0.37 ± 1.03 in the group B, respectively. The overall mean number of attacks was 4.75 ± 5.75 and 1.68 ± 1.68 before and after treatment, respectively (Tables 4 and 5).

The mean number of attacks was lower in group B than in group A. In fact, there was no significant difference between the two groups in terms of attacks before a treatment based on the Mann-Whitney U
Evaluation of the Efficacy of Levetiracetam Plus Iron in Comparison With Iron Alone ...

non-parametric test results (P = 0.072). However, there was a significant difference between the two groups regarding the number of attacks after treatment (P = 0.003). Thirteen (46.4%) and 15 (53.6%) patients in group A experienced repeated attacks and no attacks compared to four (12.5%) and 28 (87.5%) patients in group B, respectively. In general, 17 patients (28.3%) experienced repeated attacks, while 43 patients (71.7%) did not have further attacks (Table 5, Figure 6).

BHS is defined as an attack following an initial stressful event such as anger, grief, and fear, a painful stimulus such as falling and head trauma, or any other psychological distress (1). Iron deficiency is the most common cause of anemia in the first 2 years of life, a period which can be observed as the BHS peak in children. Some studies have shown that anemia or low levels of red blood cells may be an etiologic factor, and iron supplements may improve BHS in children (9, 10). Levetiracetam is a new antiepileptic drug that is structurally similar to piracetam, which has been used in the treatment of BHSs. Previous studies have suggested that piracetam is an anxiety stabilizing agent, and therefore, improves BHSs (12). Levetiracetam has fast and complete digestive absorption, but its protein binding is small. It is metabolized with the hydrolysis of the enzyme, but is independent of the P450 cytochrome system. The drug and its metabolites are excreted through the urine and have a half-life of about 6-8 hours. The drug does not interact with other antiepileptic drugs, and also, does not affect the pharmacokinetics of other drugs such as contraceptive drugs, digoxin, and warfarin. It is used as an adjunct to control general and partial epilepsy. The exact mechanism of levetiracetam is still unknown, but its side effects are extremely small and do not require any testing (14). This study was conducted on 60 patients with BHS admitted to the Shahid Motahari Hospital of Urmia to examine the efficacy of the combination of Levetiracetam and iron compared to iron alone in two treatment groups: group A with 28 patients receiving only ferrous sulfate and group B with 32 patients receiving ferrous sulfate and Levetiracetam.

Group A consisted of 17 boys and 11 girls, and the group B consisted of 11 boys and 21 girls, with the overall participants being 28 boys and 32 girls. The mean age was 19.60 ± 10.32 months in group A and 17.06 ± 8.46 months in group B with the overall mean age of 18.25 ± 9.38 months. The mean number of attacks after treatment was 37 ± 1.03 in group B and 71 ± 1.99 in group A. There was no significant difference between the two groups concerning attacks before a treatment based on the Mann-Whitney U non-parametric test results (P = 0.072). However, there was a significant difference between the groups regarding attacks after treatment (P = 0.003). Thirteen patients (46.4%) in group A experienced repeated attacks compared to four patients (12.25%) in group B. Moreover, 15 patients in group A (53.6%) experienced no attacks compared to 28 patients (87.5%) in group B. In a study conducted by Mocan et al. (2000) in Turkey to assess the effect of iron supplementation on BHSs after three months, there was a significant difference between iron-treated children and controls (84.1% vs. 21.4%) regarding the reduction of cyanotic spells. They concluded that treatment for iron deficiency anemia was effective in reducing the frequency of BHS (16). However, this is not consistent with the result of our study showing a response rate of only 54% in those treated with iron alone. In a study conducted by Azam et al. (2008) in Pakistan, the effect of prophylactic piracetam was examined on severe
cases of BHS. The spells completely disappeared in 81% of children, and the number of attacks decreased to less than one per month with less severity in 9% of them. Prophylaxis was given for 3 to 6 months (average of 5 months). They concluded that piracetam was effective in preventing severe BHS (17). Considering the similarity of the chemical structure of levotiracetame to that of piracetam, the findings of their study are consistent with those of our study. In another study conducted by Ashraf Zadeh et al. (2005) in Iran, the effect of piracetam was examined on BHS. They reported that 19 (90.5%) of the children receiving piracetam had a good response, while in the group receiving the placebo, only eight children (40%) experienced no attacks (P = 0.002). The incidence of clinical complications was similar in both groups. They concluded that piracetam was an effective medication for the treatment of childhood BHS, with no major side effects (18), which is consistent with the results of our study. Some previously published studies examined the effect of piracetam and iron in comparison with iron alone on controlling BHS (19, 20). These studies reported a significant difference between the two groups concerning the frequency reduction of attacks (P=0.001), with the mean number of attacks being one spell in a month in the first group and two attacks in the second group. They concluded that treating spells with the combination of piracetam and iron was more effective than only with iron, which is compatible with the findings of our study.

Table 1. The mean age, weight, head circumference, Hb, ferritin.

| Therapeutic group | Number | Number | Age   | Weight | Head circumference | Hb    | Ferritin |
|-------------------|--------|--------|-------|--------|--------------------|-------|----------|
|                   | A      | 28     | Mean  | 19.60  | 10.27              | 45.76 | 10.86    | 24.65    |
|                   |        |        | SD    | 10.32  | 1.53               | 1.86  | 0.99     | 7.63     |
|                   |        |        | minimum | 6     | 8                  | 43    | 8/90     | 12       |
|                   |        |        | maximum | 42    | 14                 | 50    | 12/90    | 47       |
|                   | B      | 32     | Mean  | 17.06  | 10.25              | 45.62 | 10.85    | 25.02    |
|                   |        |        | SD    | 8.46   | 2.17               | 1.85  | 0.87     | 5.56     |
|                   |        |        | Minimum | 6     | 6/70               | 43    | 8/20     | 15       |
|                   |        |        | Maximum | 47    | 16                 | 49    | 12/10    | 38       |
|                   |        |        | P-value | 0.381 | 0.613              | 0.812 | 0.682    | 0.634    |
Table 2. The mean age, weight, head circumference, Hb, ferritin for all patients.

|          | Age  | Weight | Head circumference | Hb    | Ferritin |
|----------|------|--------|--------------------|-------|----------|
| Mean     | 18.25| 10.26  | 45.69              | 10.86 | 24.85    |
| SD       | 9.38 | 1.88   | 1.84               | 0.92  | 6.55     |
| Minimum  | 6    | 6.70   | 43                 | 8.20  | 12       |
| Maximum  | 47   | 16     | 50                 | 12.90 | 47       |
| P- Value | 0.381| 0.613  | 0.822              | 0.682 | 0.634    |

Table 3. Distribution of gender in treatment groups.

|       | Male | Female | Sex   | Total | P-Value |
|-------|------|--------|-------|-------|---------|
| Group | number | number | percentage | number | number | percentage |
| A     | 17    | 11     | 60.7% | 28    |         |
| B     | 11    | 21     | 34.4% | 32    |         |
| Total | 28    | 32     | 46.7% | 60    | 0.047   |

Table 4. The mean number of attacks.

| Group | Pre-treatment | Post-treatment | P-Value |
|-------|---------------|----------------|---------|
| A     | number        | 28             | 28      |
|       | mean          | 4.39           | 1.71    |
|       | SD            | 2.69           | 1.99    |
| B     | number        | 32             | 32      |
|       | mean          | 6.39           | 0.37    |
|       | SD            | 5.07           | 1.03    |
| P-Value |          | 0.072         | 0.003   |
Table 5. Repeat attacks in different groups.

| A   | Group | Total |
|-----|-------|-------|
| B   |       |       |
| Yes | Number| 13    | 4   | 17  |
|     | Percentage| 46.4%  | 12.5% | 28.3% |
| No  | Number| 15    | 28  | 43  |
|     | Percentage| 53.6%  | 87.5% | 71.7% |
| Total| Percentage| 28     | 32  | 60  |
|     | 100%   | 100%  | 100%|

Figure 1. The mean of age, weight, head circumference, HB, ferritin for Group A
Evaluation of the Efficacy of Levetiracetam Plus Iron in Comparison With Iron Alone ...

Figure 2. The mean of age, weight, head circumference, Hb, ferritin for Group B

Figure 3. Distribution of gender in the treatment group
Evaluation of the Efficacy of Levetiracetam Plus Iron in Comparison With Iron Alone ...

Figure 4. The mean age number of attacks Group A

Figure 5. The mean number of attacks in group B
In Conclusion

Based on the findings of our study, we suggest that the combination of levetiracetam and iron is more effective than iron alone in controlling BHSs. Being a safe pharmaceutical profile in children, levetiracetam can be safely used to control BHS in combination with iron.

Acknowledgment

We would like to thank the patients’ parents for their cooperation in this investigation.

Author’s contribution

Abasi E: Were responsible for the study design and interpretation of clinical data.
Ghazavi A: Supervised the study, revised and edited the manuscript.
Mohamad Vand Matinkhah M: collected the data.
Hassanvand Amouzadeh M: Wrote the first draft of this manuscript.
All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. Leung AK, Leung AA, Wong AH, Hon KL. Breath-Holding Spells in Pediatrics: A Narrative Review of the Current Evidence. Current pediatric reviews. 2019;15(1):22-9.
2. Calik M, Abuhandan M, Aycicek A, Taskin A, Selek S, Iscan A. Increased oxidant status in children with breath-holding spells. Child’s Nervous System. 2013;29(6):1015-9.
3. Patel AD, Berg AT, Billinghamurst L, Fain D, Fecske E, Feyma T, et al. Quality improvement in neurology: child neurology quality measure set: executive summary. Neurology. 2018;90(2):67-73.
4. Bhavanishankar R, Ramu P, Chaitanya N.
Clinical and Epidemiological Profile of Breath Holding Spells (BHS)-an Analysis of 115 Cases. Journal of Evolution of Medical and Dental Sciences. 2018;7(4):534-40.

5. Jain R, Omanakuttan D, Singh A, Jajoo M. Effect of iron supplementation in children with breath holding spells. Journal of paediatrics and child health. 2017;53(8):749-53.

6. Tomoum H, Habeeb N, Elagouza I, Mobarez H. Paediatric breath-holding spells are associated with autonomic dysfunction and iron deficiency may play a role. Acta Paediatrica. 2018;107(4):653-7.

7. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience. 2015;16(6):358.

8. Zhang W, Wang C, Zou R, Liu L, Wu L, Luo X, et al. Changes in P-wave, T-wave, and ST segment amplitude in 12 lead electrocardiogram in children with breath holding spell. Zhong nan da xue xue bao Yi xue ban= Journal of Central South University Medical sciences. 2016;41(6):600-5.

9. Hussain S, Afzal M, Imam SM, Sabir MU, Tarar SH, Asghar I. Breath holding spells: demographic profile and efficacy of iron supplementation in children with breath holding spells and anemia on reduction in frequency of these spells. Pain. 2016;15:33.3.

10. Goldman RD. Breath-holding spells in infants. Canadian Family Physician. 2015;61(2):149-50.

11. Rezaeian S, Ahmadzadeh J, Esmaillnasab N, Veisani Y, Shayan M, Moradi N. Assessment of health and nutritional status in children based on school screening programs. 2014; 3(1):15-21.

12. Donma MM. Clinical efficacy of piracetam in treatment of breath-holding spells. Pediatric neurology. 1998;18(1):41-5.

13. Jain P, Gulati P, Morrison-Levy N, Yau I, Alsowat D, Otsubo H, et al. “Breath holding spells” in a child with SCN8A-related epilepsy: Expanding the clinical spectrum. Seizure-European Journal of Epilepsy. 2019;65:129-30.

14. Cramer JA, Arrigo C, Van Harn K, Gauer LJ, Cereghino JJ, Group NS. Effect of Levetiracetam on Epilepsy-Related Quality of Life. Epilepsia. 2000;41(7):868-74.

15. Akpinar M, Ocal M, İrdem A. Ventricular repolarization changes in children with breath holding spells. Journal of Electrocardiology. 2019; 55:116-9.

16. Mocan H, Yıldırın A, Orhan F, Erduran E. Breath holding spells in 91 children and response to treatment with iron. Archives of disease in childhood. 1999;81(3):261-2.

17. Azam M, Bhatti N, Shahab N. Piracetam in severe breath holding spells. The International Journal of Psychiatry in Medicine. 2008;38(2):195-201.

18. Fisher R, Saul M. Overview of epilepsy. Stanford Neurology. 2010 p.29.

19. Ghareib BA, Khalil M, Gaber DM. A comparative study of the efficacy of using piracetam with iron therapy versus iron therapy alone in children with breath-holding spells. Alexandria Journal of Pediatrics. 2017;30(1):26.

20. Bolat N, Elicak K, Sargin E, Kanik A, Baydan F, Sarioglu B. Efficacy of a Brief Psychoeducational Intervention for Mothers of Children with Breath-Holding Spells: A Randomized Controlled Pilot Trial. Neuropsychiatrics. 2016;47(04):226-32.